EA201991431A1 - УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ - Google Patents
УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫInfo
- Publication number
- EA201991431A1 EA201991431A1 EA201991431A EA201991431A EA201991431A1 EA 201991431 A1 EA201991431 A1 EA 201991431A1 EA 201991431 A EA201991431 A EA 201991431A EA 201991431 A EA201991431 A EA 201991431A EA 201991431 A1 EA201991431 A1 EA 201991431A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- systems
- methods
- transmissed
- transfer genes
- associated compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Reinforced Plastic Materials (AREA)
Abstract
В настоящем изобретении предусмотрены различные транспозазы и транспозоны TcBuster, системы и способы их применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435522P | 2016-12-16 | 2016-12-16 | |
PCT/US2017/066829 WO2018112415A1 (en) | 2016-12-16 | 2017-12-15 | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991431A1 true EA201991431A1 (ru) | 2020-01-17 |
Family
ID=62559537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991431A EA201991431A1 (ru) | 2016-12-16 | 2017-12-15 | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ |
Country Status (10)
Country | Link |
---|---|
US (5) | US11111483B2 (ru) |
EP (1) | EP3555273B1 (ru) |
JP (1) | JP7275043B2 (ru) |
KR (1) | KR102523318B1 (ru) |
CN (1) | CN110730821B (ru) |
AU (1) | AU2017378482B2 (ru) |
CA (1) | CA3047313A1 (ru) |
EA (1) | EA201991431A1 (ru) |
IL (1) | IL267334A (ru) |
WO (1) | WO2018112415A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー-モーゲン・バイオテクノロジーズ,インコーポレーテッド | 増大したhATファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
JP2021527427A (ja) | 2018-06-21 | 2021-10-14 | ビー−モーゲン・バイオテクノロジーズ,インコーポレーテッド | 強化されたhATファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 |
AU2021268649A1 (en) * | 2020-05-04 | 2022-10-20 | Saliogen Therapeutics, Inc. | Transposition-based therapies |
EP4161950A4 (en) * | 2020-06-05 | 2024-06-26 | B-Mogen Biotechnologies, Inc. | ENHANCED GENE TRANSFER MEDIATED BY HAT FAMILY SPIN TRANSPOSON AND RELATED COMPOSITIONS, SYSTEMS AND METHODS |
CN111607661B (zh) * | 2020-06-29 | 2022-06-14 | 北部湾大学 | 基于油茶转录组hAT转座子的分子标记引物组及其应用 |
CN111607662B (zh) * | 2020-06-30 | 2022-06-10 | 北部湾大学 | 基于白骨壤转录组hAT转座子的分子标记引物组及其应用 |
WO2023282730A1 (ko) * | 2021-07-09 | 2023-01-12 | 주식회사 네오젠티씨 | 트랜스포존 시스템 및 이의 용도 |
US20230081881A1 (en) | 2021-07-21 | 2023-03-16 | Aspen Neuroscience, Inc. | Transposon-based modulation of gba1 and related compositions and uses thereof |
WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2431246A1 (en) | 2000-12-05 | 2002-06-13 | Wisconsin Alumni Research Foundation | Double transposition methods for manipulating nucleic acids |
US7064246B2 (en) | 2001-05-01 | 2006-06-20 | Macrae Amy F | Use of transposable elements for altering gene expression |
US7262056B2 (en) | 2001-11-08 | 2007-08-28 | Mirus Bio Corporation | Enhancing intermolecular integration of nucleic acids using integrator complexes |
EP1458875A2 (de) | 2001-12-20 | 2004-09-22 | Sungene GmbH & Co. KGaA | Verfahren zur transformation von pflanzlichen plastiden |
US20080008687A1 (en) | 2003-02-10 | 2008-01-10 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) | Transposon-Based Targeting System |
US8420386B2 (en) | 2003-02-10 | 2013-04-16 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) | Transposon-based targeting system |
US7985739B2 (en) * | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
GB2403475B (en) | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
US20060252140A1 (en) | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
EP2392657B1 (en) | 2005-07-05 | 2013-09-25 | The Chemo-Sero-Therapeutic Research Institute | Modified transposon vector and its use |
JP5726522B2 (ja) | 2007-07-04 | 2015-06-03 | マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン | トランスポゾンシステム−スリーピングビューティーのトランスポザーゼタンパク質の機能亢進性バリアント |
US8524979B2 (en) | 2008-04-14 | 2013-09-03 | National Taiwan University | Termination of transgene expression via transposon-mediated break |
US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
EP2401367B1 (en) | 2009-02-26 | 2016-11-30 | Transposagen Biopharmaceuticals, Inc. | Hyperactive piggybac transposases |
CN102803484A (zh) | 2009-06-11 | 2012-11-28 | 大学共同利用机关法人情报·***研究机构 | 生产蛋白质的方法 |
TR201820015T4 (tr) | 2010-12-09 | 2019-01-21 | Univ Pennsylvania | Kanser Tedavisi İçin Kimerik Antijen Reseptörü-Modifiye Edilmiş T Hücrelerinin Kullanılması |
US20130017978A1 (en) | 2011-07-11 | 2013-01-17 | Finnzymes Oy | Methods and transposon nucleic acids for generating a dna library |
US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
US9738874B2 (en) * | 2011-12-16 | 2017-08-22 | Novozymes Inc. | Polypeptides having laccase activity and polynucleotides encoding same |
EP3415158B1 (en) | 2012-03-15 | 2020-11-11 | Cellectis | Repeat variable diresidues for targeting nucleotides |
CN102690354B (zh) * | 2012-05-14 | 2015-03-25 | 安源生物科技(上海)有限公司 | 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达*** |
PT2692865E (pt) | 2012-07-30 | 2015-02-06 | Nbe Therapeutics Llc | Identificação mediada por transposição de proteínas funcionais ou de ligação específicas |
DK3536797T3 (da) | 2013-02-01 | 2023-04-03 | Selexis Sa | Forhøjet transgenudtrykkelse og -forarbejdning |
CN112795594A (zh) | 2013-05-14 | 2021-05-14 | 得克萨斯州大学***董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
PL3083671T3 (pl) * | 2013-12-20 | 2021-03-22 | Fred Hutchinson Cancer Center | Znakowane chimeryczne cząsteczki efektorowe i ich receptory |
US20170216456A1 (en) | 2014-03-21 | 2017-08-03 | The Sydney Children's Hospitals Network (Randwick and Westmead)(Incorporating the Royal Alexandra | Stable Gene Transfer to Proliferating Cells |
CN103981204B (zh) | 2014-03-24 | 2016-05-04 | 上海海洋大学 | 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法 |
WO2015157579A2 (en) | 2014-04-09 | 2015-10-15 | Dna2.0, Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
JP2017518082A (ja) | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス, インコーポレイテッド | ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用 |
AU2015323973A1 (en) | 2014-09-29 | 2017-04-20 | The Jackson Laboratory | High efficiency, high throughput generation of genetically modified mammals by electroporation |
EP3018200A1 (en) | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
US20180080051A1 (en) | 2015-03-31 | 2018-03-22 | Exeligen Scientific, Inc. | Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism |
CN107980059B (zh) | 2015-04-13 | 2022-11-11 | 美克斯细胞有限公司 | 用于修饰基因组dna的方法和组合物 |
WO2016191618A1 (en) | 2015-05-27 | 2016-12-01 | Jianbiao Zheng | Methods of inserting molecular barcodes |
CN108026519A (zh) | 2015-06-17 | 2018-05-11 | 波赛达治疗公司 | 将蛋白质定向至基因组中的特定基因座的组合物和方法 |
ES2772709T3 (es) | 2015-09-16 | 2020-07-08 | T Curx Gmbh | Sistema mejorado de transposón para la administración de genes |
EA201890772A1 (ru) | 2015-09-22 | 2018-10-31 | Юлиус Максимилианс-Универзитет Вюрцбург | Способ высокоуровневого и стабильного переноса генов в лимфоцитах |
CN105154473B (zh) | 2015-09-30 | 2019-03-01 | 上海细胞治疗研究院 | 一种高效安全的转座子整合***及其用途 |
CN108138171B (zh) | 2015-10-08 | 2022-05-13 | 国立大学法人名古屋大学 | 表达嵌合抗原受体的基因修饰t细胞的制备方法 |
JP6956416B2 (ja) * | 2015-12-14 | 2021-11-02 | ゲノムフロンティア セラピューティクス,インコーポレイテッド | トランスポゾン系、それを含むキット及びそれらの使用 |
WO2017123758A1 (en) | 2016-01-12 | 2017-07-20 | Seqwell, Inc. | Compositions and methods for sequencing nucleic acids |
ES2903408T3 (es) | 2016-02-25 | 2022-04-01 | Cell Medica Switzerland Ag | Miembros de unión para PD-L1 |
JP2019506177A (ja) | 2016-02-26 | 2019-03-07 | ポセイダ セラピューティクス, インコーポレイテッド | トランスポゾン系および使用方法 |
EP3219800A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
EP3436572A4 (en) | 2016-03-31 | 2019-11-20 | Lion TCR Pte. Ltd. | NON-ACTIVATED T LYMPHOCYTES EXPRESSING EXOGENIC VIRUS SPECIFIC T CELL LYMPHOCYTE T RECEPTOR (TCR) |
US11723962B2 (en) | 2016-05-04 | 2023-08-15 | Fred Hutchinson Cancer Center | Cell-based neoantigen vaccines and uses thereof |
CN107523547A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抑制性抗体的car‑t细胞及其用途 |
CN107523545A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
CN114891751A (zh) | 2016-06-20 | 2022-08-12 | 上海细胞治疗研究院 | 一种高效稳定表达激活型抗体的car-t细胞及其用途 |
CN107523548A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的t细胞及其用途 |
WO2018015936A2 (en) | 2016-07-21 | 2018-01-25 | Maxcyte, Inc. | Methods and compositions for modifying genomic dna |
EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
JP6943376B2 (ja) | 2016-08-30 | 2021-09-29 | 国立大学法人九州大学 | Dna結合タンパク質の結合領域の近傍に所望のdna断片を挿入する方法 |
WO2018057779A1 (en) | 2016-09-23 | 2018-03-29 | Jianbiao Zheng | Compositions of synthetic transposons and methods of use thereof |
CA3036926C (en) | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
CN110494565A (zh) | 2016-12-02 | 2019-11-22 | 朱诺治疗学股份有限公司 | 工程化b细胞及相关组合物和方法 |
JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー-モーゲン・バイオテクノロジーズ,インコーポレーテッド | 増大したhATファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
US11692194B2 (en) | 2017-01-10 | 2023-07-04 | Precigen, Inc. | Modulating expression of polypeptides via new gene switch expression systems |
WO2018140644A1 (en) | 2017-01-25 | 2018-08-02 | Musc Foundation For Research Development | Modified t cells and uses thereof |
-
2017
- 2017-12-15 JP JP2019554474A patent/JP7275043B2/ja active Active
- 2017-12-15 EA EA201991431A patent/EA201991431A1/ru unknown
- 2017-12-15 KR KR1020197020507A patent/KR102523318B1/ko active IP Right Grant
- 2017-12-15 AU AU2017378482A patent/AU2017378482B2/en active Active
- 2017-12-15 US US15/844,363 patent/US11111483B2/en active Active
- 2017-12-15 EP EP17880424.1A patent/EP3555273B1/en active Active
- 2017-12-15 WO PCT/US2017/066829 patent/WO2018112415A1/en unknown
- 2017-12-15 CA CA3047313A patent/CA3047313A1/en active Pending
- 2017-12-15 CN CN201780086768.7A patent/CN110730821B/zh active Active
-
2018
- 2018-04-20 US US15/958,834 patent/US20180245055A1/en not_active Abandoned
- 2018-06-11 US US16/005,270 patent/US10227574B2/en active Active
-
2019
- 2019-06-13 IL IL267334A patent/IL267334A/en unknown
-
2020
- 2020-02-12 US US16/789,188 patent/US11162084B2/en active Active
-
2021
- 2021-10-22 US US17/508,522 patent/US20220112472A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200339965A1 (en) | 2020-10-29 |
KR20190142313A (ko) | 2019-12-26 |
US20180327726A1 (en) | 2018-11-15 |
US11111483B2 (en) | 2021-09-07 |
US20180216087A1 (en) | 2018-08-02 |
KR102523318B1 (ko) | 2023-04-18 |
AU2017378482B2 (en) | 2024-06-13 |
JP2020501612A (ja) | 2020-01-23 |
IL267334A (en) | 2019-08-29 |
EP3555273A1 (en) | 2019-10-23 |
EP3555273B1 (en) | 2024-05-22 |
JP7275043B2 (ja) | 2023-05-17 |
US10227574B2 (en) | 2019-03-12 |
WO2018112415A1 (en) | 2018-06-21 |
CN110730821A (zh) | 2020-01-24 |
US20180245055A1 (en) | 2018-08-30 |
EP3555273A4 (en) | 2020-12-09 |
US20220112472A1 (en) | 2022-04-14 |
US11162084B2 (en) | 2021-11-02 |
CN110730821B (zh) | 2023-12-08 |
CA3047313A1 (en) | 2018-06-21 |
AU2017378482A1 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991431A1 (ru) | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ | |
EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
TR201901445T4 (tr) | Il2rbeta/yaygın gamma zinciri antikorları. | |
EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
MX2019007020A (es) | Anticuerpos il-11. | |
EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890051A1 (ru) | Композиции, содержащие бактериальные штаммы | |
MX2019007021A (es) | Anticuerpos il-11ra. | |
MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
EA201691991A1 (ru) | Мультиспецифические антитела | |
BR112017003414A2 (pt) | composições compreendendo caseína e métodos para produzir as mesmas | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
MX2019005322A (es) | Composiciones de recubrimiento y metodos de uso de las mismas. |